Skip to main content
. 2026 Jan 9;14:e20536. doi: 10.7717/peerj.20536

Table 1. Baseline biochemical and procedural characteristics and medications and lifestyle of the study participants.

Variable Total
(n = 860)
HPR group
(n = 335)
NPR group
(n = 224)
LPR group
(n = 301)
P
value
Patient characteristics
Age, years 63.81 ± 10.17 63.86 ± 9.83 63.66 ± 10.15 63.86 ± 10.58 0.96
Age >75 years 136 (15.81%) 48 (14.32%) 33 (14.73%) 55 (18.27%) 0.35
Female 257 (29.88%) 126 (37.61%) 58 (25.89%) 73 (24.25%) <0.001
BMI, kg/m2 24.11 ± 3.30 24.52 ± 3.30 24.22 ± 3.38 23.58 ± 3.22 0.001
SBP, mmHg 133.15 ± 22.59 135.43 ± 21.99 133.70 ± 22.33 130.20 ± 23.18 0.013
DBP, mmHg 78.17 ± 12.67 79.06 ± 12.15 78.77 ± 12.85 76.74 ± 13.02 0.050
Hypertension 614 (71.40%) 254 (75.82%) 163 (72.77%) 197 (65.45%) 0.013
Diabetes mellitus 429 (49.88%) 178 (53.13%) 118 (52.68%) 133 (44.19%) 0.049
Smokers 463 (53.84%) 159 (47.46%) 126 (56.25%) 178 (59.14%) 0.009
PVD 363 (42.21%) 152 (45.37%) 100 (44.64%) 111 (36.87%) 0.066
Heart failure
(I–III)
158 (18.37%) 59 (17.61%) 38 (26.34%) 61 (20.27%) 0.57
eGFR base line (ml/min/1.73 m2) 71.84 ± 30.41 70.73 ± 28.00 74.52 ± 37.43 71.08 ± 25.71 0.31
CKD 49 (5.70%) 19 (2.21%) 13 (5.80%) 17 (1.98%) 0.99
TIA/Stroke 118 (13.72%) 45 (13.43%) 35 (15.63%) 38 (12.62%) 0.60
Previous PCI 104 (12.09%) 51 (15.22%) 35 (15.63%) 18 (5.98%) <0.001
Previous CABG 5 (0.58%) 2 (0.23%) 1 (0.45%) 2 (0.66%) 0.95
ACS 535 (62.21%) 223 (66.57%) 151 (67.41%) 160 (53.16%) <0.001
Angiographic data and treatment
LCA 65 (7.56%) 28 (7.89%) 13 (5.80%) 24 (7.16%) 0.51
LAD 804 (93.49%) 308 (91.94%) 212 (94.64%) 284 (94.35%) 0.34
IABP 11 (1.28%) 5 (1.49%) 2 (0.89%) 4 (1.33%) 0.82
Laboratory
WBC,109 /L 8.18 ± 3.37 7.73 ± 2.64 8.10 ± 3.48 8.76 ± 3.88 <0.001
Hb, g/L 131.24 ± 17.77 128.81 ± 17.64 132.62 ± 17.32 132.94 ± 18.11 0.006
Platelet 211.41 ± 61.96 208.77 ± 60.41 210.67 ± 59.03 214.89 ± 65.53 0.46
LDL cholesterol 2.31 ± 0.87 2.28 ± 0.89 2.25 ± 0.76 2.39 ± 0.87 0.16
HDL cholesterol 1.14 ± 0.27 1.14 ± 0.26 1.12 ± 0.28 1.14 ± 0.26 0.72
Triglycerides, mmol/L 1.74 ± 1.36 1.83 ± 1.47 1.69 ± 1.30 1.67 ± 1.20 0.29
Total cholesterol, mmol/L 4.43 ± 1.26 4.43 ± 1.40 4.33 ± 1.08 4.49 ± 1.18 0.40
Baseline LVEF, % 57.49 ± 12.01 58.78 ± 11.20 57.52 ± 12.05 55.92 ± 11.34 0.007
VASP-PRI, % 37.4 ± 24.3 63.34 ± 11.62 34.17 ± 0.06 10.13 ± 8.90 <0.001
Medications
Ticagrelor 250 (29.07%) 21 (6.25%) 54 (24.11%) 175 (58.14%) <0.001
ACEI 582 (67.67%) 233 (69.55%) 149 (66.52%) 200 (65.79%) 0.64
ARB 133 (15.47%) 62 (18.51%) 34 (15.18%) 37 (12.29%) 0.095
Beta-blocker 696 (80.93%) 268 (80.00%) 182 (81.25%) 246 (81.73%) 0.85
Calcium antagonist 287 (33.37%) 133 (39.70%) 70 (31.25%) 84 (27.91%) 0.005
Statins 850 (98.84%) 333 (99.40%) 218 (97.32%) 299 (99.34%) 0.048
GPIIb/IIIa inhibitors 377 (43.84%) 133 (39.70%) 89 (39.73%) 155 (51.49%) 0.004
Nitrates 423 (49.19%) 165 (49.25%) 110 (49.11%) 148 (49.17%) 0.99
Proton pump inhibitor 708 (82.33%) 274 (81.79%) 117 (52.23%) 257 (85.38%) <0.001

Notes.

Data are expressed as mean ± SD or number of patients or percent (%).

BMI
body mass index
SBP
systolic blood pressure
DBP
diastolic blood pressure
PVD
peripheral vascular disease
CKD
chronic kidney disease
TIA
transient ischemic attack
PCI
percutaneous coronary intervention
CABG
coronary artery bypass grafting
ACS
acute coronary syndrome
LCA
left coronary artery
LAD
left anterior descending artery
IABP
intra-aortic balloon pump
WBC
white blood cell
Hb
hemoglobin
LDL
low-density lipoprotein cholesterol
HDL
high-density lipoprotein cholesterol
LVEF
left Ventricular Ejection Fraction
VASP-PRI
vasodilator-stimulated phosphoprotein-platelet reactivity index
ACEI
angiotensin-converting enzyme inhibitor
ARB
angiotensin receptor blocker